News
-
-
-
-
-
-
PRESS RELEASE
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Formycon AG invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences. Management Board to discuss key financial figures and recent uplisting to the Prime Standard of Frankfurt Stock Exchange -
-
-
PRESS RELEASE
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
Formycon receives positive CHMP opinion for FYB203, a biosimilar candidate to Eylea, under tradenames AHZANTIVE and Baiama. Approval decision by European Commission expected in January 2025 -